STOCK TITAN

Vishwas Seshadri plans ABEO (ABEO) stock sale of 69,832 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Abeona Therapeutics (ABEO) insider Vishwas Seshadri has filed a notice of proposed stock sales under Rule 144. The filing covers 69,832 shares of common stock to be sold through Stifel Nicolaus & Company on the Nasdaq exchange, with an aggregate market value of 372,267.00. The filing notes that 54,191,361 shares of common stock were outstanding.

The securities to be sold were acquired on 01/21/2026 as 158,811 restricted stock units from the issuer, characterized as equity compensation, with the payment date listed as 01/22/2026. The document also reports that Seshadri sold 25,000 shares of common stock on 12/29/2025, generating gross proceeds of 132,740.00 over the prior three months.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many ABEO shares does Vishwas Seshadri plan to sell under this Form 144 notice?

The notice states that 69,832 shares of Abeona Therapeutics common stock are planned to be sold through Stifel Nicolaus & Company on the Nasdaq exchange, with an aggregate market value of 372,267.00.

What is the total number of Abeona Therapeutics (ABEO) shares outstanding referenced in the Form 144?

The filing reports that 54,191,361 shares of Abeona Therapeutics common stock were outstanding, providing context for the planned sale amount.

How did Vishwas Seshadri acquire the ABEO shares listed for sale in this Form 144?

The Form 144 shows that the securities were acquired as restricted stock units from the issuer on 01/21/2026, in a transaction described as equity compensation, with the payment date listed as 01/22/2026.

What prior ABEO stock sales by Vishwas Seshadri are disclosed in the last 3 months?

The filing discloses that 25,000 shares of Abeona Therapeutics common stock were sold on 12/29/2025, generating gross proceeds of 132,740.00 over the past three months.

Which broker is handling the planned ABEO share sale in this Form 144?

The document lists Stifel Nicolaus & Company Inc., located at 501 N Broadway, St. Louis, MO 63102, as the broker for the planned sale of Abeona Therapeutics common stock on Nasdaq.

What is the approximate date of the planned ABEO stock sale in the Form 144?

The Form 144 indicates an approximate sale date of 01/22/2026 for the planned disposition of 69,832 shares of Abeona Therapeutics common stock.
Abeona Therapeut

NASDAQ:ABEO

View ABEO Stock Overview

ABEO Rankings

ABEO Latest News

ABEO Latest SEC Filings

ABEO Stock Data

257.95M
45.93M
Biotechnology
Pharmaceutical Preparations
Link
United States
CLEVELAND